PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808835
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808835
Digital biomanufacturing market size was valued at US$ 21,234.65 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.
Digital biomanufacturing is the integration of digital technologies, such as artificial intelligence, machine learning, data analytics, and automation, into biological production processes. It enhances efficiency, precision, and scalability in the manufacturing of biologics, vaccines, and cell and gene therapies. By enabling real-time monitoring, predictive maintenance, and process optimization, digital biomanufacturing improves product quality, reduces costs, and accelerates development timelines, revolutionizing the future of biotechnology and pharmaceutical production.
Digital Biomanufacturing Market- Market Dynamics
Increasing demand for biologics is expected to propel the market demand
Rising demand for biologics is accelerating digital transformation in manufacturing, with the U.S. FDA reporting that biologics accounted for over 45% of new drug approvals in 2023. Besides, the growing government focus on smart manufacturing is driving the adoption of digital biomanufacturing. However, complex regulatory compliance and high capital investment are major barriers for the global digital biomanufacturing market. On the contrary, the expansion of AI in manufacturing presents a strong opportunity for market growth. Moreover, supportive public funding for innovation is growing, including digital infrastructure and automation.
Digital Biomanufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.5% over the forecast period (2025-2032)
Based on Biologic Type segmentation, antibodies were predicted to show maximum market share in the year 2024
Based on Deployment Type segmentation, on-premises was the leading Deployment Type in 2024
Based on Application segmentation, biomanufacturing process automation was the leading Application in 2024
Based on technology segmentation, process analytical technology (PAT) was the leading technology in 2024
Based on end user segmentation, biopharmaceutical companies were the leading end user in 2024
Based on region, North America was the leading revenue generator in 2024
The Global Digital Biomanufacturing Market is segmented on the basis of Biologic Type, Deployment Type, Application, Technology, End User, and Region.
The market is divided into four categories based on Biologic Type: antibodies, vaccines, cell & gene therapies, and others. The antibodies segment is expected to hold the major market share during the forecast period. This is due to their widespread use in treating chronic diseases like cancer and autoimmune disorders, along with high production volumes and continuous demand for monoclonal antibodies.
The market is divided into four categories based on Application: digital bioreactor scaling, remote equipment monitoring, biomanufacturing process automation, and others. The biomanufacturing process automation segment is expected to hold the major market share. This dominance is driven by the need to enhance efficiency, reduce human error, and streamline complex production workflows.
Digital Biomanufacturing Market- Geographical Insights
North America is expected to hold the major market share in the global digital biomanufacturing market during the forecast period, driven by advanced biotechnology infrastructure, strong government funding, and early adoption of AI and automation technologies.
On the other hand, Asia-Pacific is projected to grow at the fastest rate, fueled by expanding biopharmaceutical manufacturing hubs, increasing investments in digital healthcare technologies, and supportive government initiatives in countries like China, India, and South Korea.
Growing demand for faster and more precise biologics production is driving competition, prompting companies to adopt strategies centered on digital integration, automation, and real-time analytics. Firms are investing in smart manufacturing platforms, AI-driven process control, and digital twins to optimize production efficiency and reduce time-to-market. Strategic collaborations with tech providers, expansion of cloud-based solutions, and development of modular bioproduction systems are also gaining traction, enabling players to enhance flexibility, ensure regulatory compliance, and maintain a competitive edge in an evolving industry landscape.
In April 2025, Sartorius Stedim Biotech partnered with Tulip Interfaces to launch Biobrain(R) Operate, a no-code digital suite enhancing single-use bioprocessing by integrating seamlessly with Sartorius equipment, accelerating digital transformation in biopharmaceutical manufacturing.